Literature DB >> 15567416

Structural requirements and mechanism for heparin-dependent activation and tetramerization of human betaI- and betaII-tryptase.

Jenny Hallgren1, Susanne Lindahl, Gunnar Pejler.   

Abstract

Tryptase, a tetrameric serine protease, is a main constituent of the secretory granules in human mast cells, where it is stored in complex with heparin or chondroitin sulfate proteoglycan. Human tryptase has been implicated in a variety of clinical conditions including asthma, but the mechanisms that lead to its tetramerization/activation have not been extensively investigated. Here we addressed the activation mechanisms for human betaI and betaII-tryptase, which differ in that betaI-tryptase is N-glycosylated at Asn102 whereas betaII-tryptase has a Lys residue at position 102, and consequently lacks the corresponding N-glycosylation. We found that both tryptases were dependent on heparin for activation/tetramerization, but whereas betaI-tryptase activation preferentially occurred at acidic pH, betaII-tryptase activation was less pH-dependent. Both betaI and betaII-tryptase bound strongly to heparin-Sepharose at acidic pH but with lower affinity at neutral pH. Further, while addition of heparin to betaI-tryptase predominantly resulted in formation of active tetrameric enzyme, betaII-tryptase showed a tendency to form inactive aggregates. betaI and betaII-tryptase were similar in that the minimal heparin size to induce activation was an octasaccharide and in that the interaction with heparin and structurally related polysaccharides was dependent on high anionic charge density rather than on specific structural motifs. Addition of decasaccharides to both betaI and betaII-tryptase resulted in the formation of active monomeric enzyme, whereas intact heparin promoted assembly of tetrameric enzyme. This, together with a bell-shaped dose response curve for heparin-induced activation, suggests that the mechanism for tetramerization involves bridging of individual tryptase monomers by heparin. Taken together, this study indicates a key role for heparin in the activation of human beta-tryptase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15567416     DOI: 10.1016/j.jmb.2004.10.029

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

2.  Allosteric control of βII-tryptase by a redox active disulfide bond.

Authors:  Kristina M Cook; H Patrick McNeil; Philip J Hogg
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 3.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

Review 4.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

5.  Mouse mast cell protease-6 and MHC are involved in the development of experimental asthma.

Authors:  Yue Cui; Joakim S Dahlin; Ricardo Feinstein; Lora G Bankova; Wei Xing; Kichul Shin; Michael F Gurish; Jenny Hallgren
Journal:  J Immunol       Date:  2014-10-15       Impact factor: 5.422

6.  Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations.

Authors:  Neil N Trivedi; Bani Tamraz; Catherine Chu; Pui-Yan Kwok; George H Caughey
Journal:  J Allergy Clin Immunol       Date:  2009-09-12       Impact factor: 10.793

Review 7.  Modulation of the Plasma Kallikrein-Kinin System Proteins Performed by Heparan Sulfate Proteoglycans.

Authors:  Guacyara Motta; Ivarne L S Tersariol
Journal:  Front Physiol       Date:  2017-07-11       Impact factor: 4.566

Review 8.  Mast cell glycosaminoglycans.

Authors:  B Mulloy; R Lever; C P Page
Journal:  Glycoconj J       Date:  2016-11-30       Impact factor: 2.916

9.  Mast Cell β-Tryptase Is Enzymatically Stabilized by DNA.

Authors:  Sultan Alanazi; Mirjana Grujic; Maria Lampinen; Ola Rollman; Christian P Sommerhoff; Gunnar Pejler; Fabio Rabelo Melo
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

10.  Bivalent antibody pliers inhibit β-tryptase by an allosteric mechanism dependent on the IgG hinge.

Authors:  Henry R Maun; Rajesh Vij; Benjamin T Walters; Ashley Morando; Janet K Jackman; Ping Wu; Alberto Estevez; Xiaocheng Chen; Yvonne Franke; Michael T Lipari; Mark S Dennis; Daniel Kirchhofer; Claudio Ciferri; Kelly M Loyet; Tangsheng Yi; Charles Eigenbrot; Robert A Lazarus; James T Koerber
Journal:  Nat Commun       Date:  2020-12-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.